Stomach Cancer Treatment

Global Stomach Cancer Treatment Market to Reach ## by 2030

The global market for Stomach Cancer Treatment estimated at ## in the year 2024, is expected to reach ## by 2030, growing at a CAGR of 0.0% over the analysis period 2024-2030.

Global Stomach Cancer Treatment Market – Key Trends & Drivers Summarized

Why Is Stomach Cancer Treatment Receiving Renewed Global Focus Across Healthcare Systems?

Stomach cancer, or gastric cancer, remains one of the leading causes of cancer-related mortality worldwide, particularly in East Asia, Eastern Europe, and parts of Latin America. While overall incidence is declining in some regions due to improved food safety, Helicobacter pylori eradication, and early screening efforts, it continues to pose a significant health challenge due to late-stage diagnosis and limited treatment accessibility in many countries. The global healthcare community is shifting its focus toward stomach cancer due to rising awareness, expanded screening initiatives, and improvements in data collection that underscore the disease`s true burden. In high-risk countries such as Japan, South Korea, and China, organized screening programs are detecting more cases at an earlier, potentially curable stage—driving a surge in demand for curative surgical and pharmacologic interventions. In the West, where stomach cancer tends to present at more advanced stages, there is growing clinical attention on novel systemic therapies that can extend survival and improve quality of life. This renewed focus is pushing pharmaceutical innovation, health system planning, and academic research into more coordinated, strategic efforts to manage and eventually reduce stomach cancer mortality on a global scale.

How Are Targeted Therapies and Immuno-Oncology Redefining the Treatment Landscape?

The stomach cancer treatment landscape is undergoing a major transformation fueled by advances in precision medicine, biomarker testing, and immunotherapy. Traditionally treated with surgery, chemotherapy, and radiation, stomach cancer is now being managed with more tailored approaches that consider molecular subtypes, genetic mutations, and PD-L1 expression levels. HER2-targeted therapies, such as trastuzumab, have significantly improved outcomes for patients with HER2-positive gastric cancer, while new antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors are expanding the arsenal against other oncogenic drivers. Immune checkpoint inhibitors like pembrolizumab and nivolumab have shown promising results in patients with advanced or metastatic gastric cancer, particularly in those with high microsatellite instability (MSI-H) or elevated tumor mutational burden (TMB). Combination therapies—pairing immunotherapy with chemotherapy or anti-angiogenic agents—are being explored to overcome resistance and improve response durability. Liquid biopsies and next-generation sequencing are facilitating earlier and more accurate treatment selection, ushering in an era of personalized care for stomach cancer patients. As regulatory approvals accelerate and clinical trial pipelines deepen, these therapeutic advances are expected to significantly reshape the standard of care in both first-line and refractory settings.

Where Is Market Demand Expanding, and Which Patient Populations Are Driving Treatment Needs?

Market demand for stomach cancer treatment is rising globally, with the highest patient burden concentrated in Asia-Pacific countries such as China, Japan, and South Korea, which account for over half of the world’s cases. These regions are characterized by proactive screening policies, strong government support, and well-established treatment protocols, making them hotspots for both early intervention and pharmaceutical sales. In Western countries, including the United States, Germany, and the UK, although incidence is comparatively lower, a shift toward younger-onset gastric cancer cases and high rates of advanced-stage presentation are intensifying treatment demands. Latin America, Eastern Europe, and parts of Africa are experiencing growing prevalence but face challenges related to late detection, treatment infrastructure, and drug access—highlighting opportunities for generic chemotherapy agents, biosimilars, and public health partnerships. Elderly patients, who account for a large proportion of new diagnoses, are driving demand for less toxic, more tolerable regimens, while younger patients are prompting interest in fertility-sparing treatments and long-term survivorship planning. Urbanization, dietary shifts, and persistent H. pylori infection in developing regions are also contributing to a steady expansion in the treatment-eligible population, creating pressure on healthcare systems to provide timely, effective, and affordable care.

What’s Driving the Long-term Growth of the Stomach Cancer Treatment Market Globally?

The growth in the stomach cancer treatment market is driven by a confluence of demographic trends, evolving therapeutic options, policy frameworks, and diagnostic advancements. A primary long-term driver is the aging global population, which is increasing the baseline risk for stomach cancer and expanding the pool of patients needing treatment. Advances in molecular profiling and companion diagnostics are enabling oncologists to move away from “one-size-fits-all” chemotherapy to precision-based regimens that target specific tumor biology—improving efficacy and minimizing side effects. The global expansion of cancer immunotherapy is opening new treatment windows for advanced or previously intractable cases. Governments and health organizations are investing in cancer control programs that prioritize early detection and access to care, while pharmaceutical companies are responding with intensified R&D investment, particularly in combination therapies and next-gen biologics. In parallel, emerging markets are building oncology infrastructure and reforming drug reimbursement policies, broadening access to both established and novel therapies. The increasing role of tele-oncology, electronic health records, and global clinical trial collaboration is also enhancing patient management and data-driven treatment optimization. As scientific understanding of gastric cancer deepens and therapeutic innovations continue to emerge, the stomach cancer treatment market is poised for sustained growth—anchored by its crucial role in addressing one of the world’s most aggressive and underdiagnosed malignancies.

SCOPE OF STUDY:

The report analyzes the Stomach Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment Type (Standard Chemotherapy, Targeted Therapy, Immunotherapy); Disease Indication (Gastric Cancer / Gastroesophageal Junction cancer, Gastrointestinal Stromal Tumors); Administration Route (Oral, Injectable)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• BeiGene, Ltd.
• Bristol-Myers Squibb Company
• CELLTRION INC.
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• GSK plc
• Harbour BioMed
• Imugene Limited
• Innovent Biologics, Inc.
• Ipsen Pharma
• Jiangsu Hengrui Medicine Co., Ltd.
• Merck & Co., Inc.
• Mirxes
• Mylan N.V.
• Myriad Genetics, Inc.
• Novartis AG
• Otsuka Holdings Co., Ltd.
• Pfizer Inc.
• Samsung Bioepis
• Sanofi S.A.
• TAIHO PHARMACEUTICAL CO., LTD.
• Teva Pharmaceutical Industries Ltd.
• Triumvira Immunologics
• WMT AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.